$3.71
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX's Varseta-M Receives FDA Fast-Track Designation to Treat Colorectal Cancer
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
Overview
52-week range
$1.90
$8.21
29% of range
Avg surprise (last 3)
+59.5%
Avg reaction (last 2)
+63.2%
50% positive
Latest IV / EM
82%
EM ±12.8% · $4 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.10 | $-0.14 | +28.6% | -137.0% | -3.1% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | — | $-0.06 | +100.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $0.27 | $0.18 | +50.0% | — | +129.5% | earnings |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $10M | — | $6M | $19M | $51M | — | $33M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-24M | $-20M | — | $-16M | $-1M | $23M | — | $4M |
| Net income | $-21M | $-18M | — | $-14M | $-154,000 | $24M | — | $6M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17M | $29M | $13M | $34M | $49M | $48M | $38M | $41M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $373M | $353M | $144M | $149M | $165M | $87M | $107M | $124M |
| Total assets | $381M | $359M | $152M | $158M | $175M | $98M | $121M | $139M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $79M | $39M | $53M | $51M | $55M | $73M | $121M | $162M |
| Total equity | $302M | $320M | $99M | $107M | $120M | $25M | $-456,000 | $-23M |